Top 10 Managed Healthcare Stocks To Watch Right Now: Coronado Biosciences Inc (CNDO)
Coronado Biosciences, Inc., incorporated on June 28, 2006, is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Companys two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohns disease (Crohns), ulcerative colitis (UC) and multiple sclerosis (MS), and CNDO-109, a compound that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells, for the treatment of acute myeloid leukemia (AML). In January 2011, the Company acquired the OvaMed GmbH License.
TSO
TSO is the microscopic eggs of a parasitic helminth, or worm, that is found in pigs. In September 2011, the Company filed an Investigational New Drug Application (IND) with t he United States Food and Drug Administration (FDA) and it initiated a single dose, dose escalation study in patients with Crohns in February 2012. The Phase 1 clinical trial was a multi-center, sequential dose-escalation, double-blind, placebo-controlled study, the primary objective of which was to evaluate the safety and tolerability of TSO. The trial enrolled 36 patients with Crohns ranging in age from 20 to 54 with an equal distribution of male and female patients in three single dose cohorts of orally administered 500, 2500 and 7500 ova. Each cohort had 12 patients, with nine patients receiving TSO and three receiving placebo.
CNDO-109
CNDO-109 is a lysate (disrupted CTV-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor NK cells. CTV-1 is a leukemic cell line recently re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company has worldwide rights to dev! elop and commercialize CNDO-109 activated NK cells for the treatment of cancer fro! m UCLB. In February 2012, the Company submitted an IND for the CNDO-109 activated NK cell product in the United States. The treatment of patients with CNDO-109 activated NK cells involves several steps. The activated NK cells are infused into the patient after resting NK cells are incubated with CNDO-109 for at least eight hours. Preparation of CNDO-109 activated NK cells takes about 24 hours from start to finish.
The Company competes with Centocor Ortho Biotech Inc.s Remicade , UCB S.A.s Cimzia, Abbott Laboratories Humira, Biogen Idecs Avonex, Bayer Healthcare Pharmaceuticals Betaseron, Teva Pharmaceuticals Industries, Ltd.s Copaxone and Novartis AGs Gilenya.
Advisors' Opinion:- [By CRWE]
Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, reported that it has filed a registration statement with the Securities and Exchange Commission for a proposed public offering of 2,000,000 shares of its common stock. All shares proposed to be included in the offering will be sold by the company.
- [By James E. Brumley]
The last few weeks haven't been particularly encouraging for Crohn's disease sufferers. In August, GlaxoSmithKline (NYSE: GSK) and ChemoCentryx (NASDAQ:CCXI) reported that a jointly-developed Crohn's drug, vercirnon, had failed to meet its late-stage trial endpoints. Though the in-development drug isn't dead in the water (GSK and CCXI could rework the drug, the testing regimen, or use it for other indications), it doesn't look good. Then this month - just a few days ago - Coronado Biosciences Inc. (NASDAQ:CNDO) reported that its Phase 3 trials of Crohn's disease drug TSO had also failed to meet its primary endpoints as well. Like vercirnon, CNDO isn't completely out of luck here with the treatment, but forging ahead! with fur! ther development of the treatment is grasping at straws. Crohn's sufferers don't need to give up home just yet, however - TNI Biotech Inc. (OTCMKTS:TNIB) appears to have a Crohn's treatment that works, and should be able to sidestep the problems that pl agued ChemoCentryx, GlaxoSmithKline, and Coronado Biosciences.
- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Coronado Biosciences (NASDAQ: CNDO ) has received a distressing two-star ranking.
- [By Roberto Pedone]
Coronado Biosciences (CNDO), a clinical stage biopharmaceutical company, focuses on the development of immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. This stock closed up 2.7% to $9.13 in Tuesday's trading session.
Tuesday's Range: $8.85-$9.58
52-Week Range: $4.00-$12.70
Tuesday's Volume: 1.31 million
Three-Month Average Volume: 419,038From a technical perspective, CNDO trended up here right above some near-term support at $8.79 with heavy upside volume. This move is starting to push shares of CNDO within range of triggering a near-term breakout trade. That trade will hit if CNDO manages to take out some near-term overhead resistance levels at $9.60 to $10.20 and then once it takes out more resistance at $10.35 with high volume.
Traders should now look for long-biased trades in CNDO as long as it's trending above its 50-day at $8.52 and then once it sustains a move or close above those breakout levels with volume that hits near or above 419,038 shares. If that breakout hits soon, then CNDO will set up to re-test or possibly take out its next major overhead resistance levels at $11 to $11.81. Any high-volume move above those levels will then put its all-time high at $12.70 into range for shares of CNDO.
source from
No comments:
Post a Comment